Frizzled-5

Frizzled-5 Informations sur la molécule

Nom anglais	Frizzled-5	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1	Alias de la cible	Frizzled Class Receptor 5，C2orf31，HFZ5，Frizzled 5， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 5，Fz-5，FzE5，Seven-Transmembrane Receptor Frizzled-5，Chromosome 2 Open Reading Frame 31，Frizzled (Drosophila) Homolog 5，HFz5
Phase de R&D la plus avancée	Phase 1 Clinical

Nom anglais	Frizzled-5
Alias de la cible	Frizzled Class Receptor 5，C2orf31，HFZ5，Frizzled 5， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 5，Fz-5，FzE5，Seven-Transmembrane Receptor Frizzled-5，Chromosome 2 Open Reading Frame 31，Frizzled (Drosophila) Homolog 5，HFz5
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	1
Phase de R&D la plus avancée	Phase 1 Clinical

Frizzled-5 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
Fc Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
FZ5-H5259	Human	HEK293	Human Frizzled-5 / FZD5 Protein, Fc Tag (MALS verified)				Ajouter au panier

Quantité totale1

Frizzled-5Contexte de la molécule

Frizzled-5 (FZD5) is also known as FzE5, which belongs to the G-protein coupled receptor Fz/Smo family. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. FZD5 contains one FZ (frizzled) domain. FZD5 may be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. FZD5 interacts specifically with Wnt5A to induce the beta-catenin pathway. FZD5 interacts with GOPC.

Frizzled-5Alias de la molécule

FZD5,Frizzled-5,C2orf31,,Fz-5,hFz5,FzE5

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Vantictumab	OMP-18R5; anti-Fzd7	Phase 1 Clinical	Bayer AG, Oncomed Pharmaceuticals Inc	Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Osteopetrosis; Pancreatic Neoplasms; Solid tumours	Details